

First-in-class non-opioid analgesics: Molecular mechanisms and clinical impact of suzetrigine

Rafsan Sium  

Sher-E-Bangla Medical College, Barishal-8200, Barisal, Bangladesh

Article number: 19, Received: 02-11-2025, Accepted: 20-01-2026, Published online: 22-01-2026



Copyright© 2026. This open-access article is distributed under the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HOW TO CITE THIS

Sium R. First-in-class non-opioid analgesics: Molecular mechanisms and clinical impact of suzetrigine. *Mediterr J Med Med Sci.* 2026; 2(1): 9-12. [Article number: 19]. <https://doi.org/10.5281/zenodo.18310351>

Keywords: Analgesic, clinical effect, Nav1.8 sodium channel, pain, suzetrigine

Abstract: Effective and safe pain management remains a challenge for clinicians and researchers, despite the fact that pain is one of the most common and important clinical challenges in medicine. Despite their well-established risks of addiction, tolerance, respiratory depression, and a host of other negative effects, opioid analgesics continued to be the standard treatment for moderate to severe pain for many years. Recent scientific discoveries and regulatory initiatives have encouraged the creation of non-opioid analgesics with unique modes of action. As the first in a new class of non-opioid, peripherally acting painkillers approved by the U.S. Food and Drug Administration in 2025, suzetrigine, marketed as JournavxTM-represents a significant milestone. This article synthesizes current knowledge on the pharmacology, molecular mechanism, clinical efficacy, safety, and potential impact of suzetrigine in pain management.

Introduction

Millions of people worldwide suffer from acute and chronic pain, which is a major contributor to disability and medical usage [1]. Strong analgesics are often needed for acute pain, such as that which follows surgery, an injury, or an acute medical condition [2, 3]. When acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) are insufficient to relieve pain, opioids such as morphine and hydrocodone have historically been prescribed [4-6]. Suzetrigine is an oral, non-opioid, selective inhibitor of the voltage-gated sodium channel Nav1.8 that was recently authorized for the treatment of moderate-to-severe acute pain in adults [7]. It was originally known as VX-548 and is currently marketed under the approved brand name JournavxTM [8]. Nav1.8 is preferentially expressed on peripheral nociceptive neurons and mediates pain sensation [9-11]. Suzetrigine has analgesic benefits without the central nervous system (CNS) adverse effects of conventional opioid analgesics by limiting its actions on peripheral nociceptive neurons [12]. Suzetrigine's effectiveness and safety in neuropathic and post-surgical pain models have been evaluated in several early and late-phase clinical studies. Suzetrigine showed comparable efficacy to hydrocodone/acetaminophen (HB/APAP) treatment and significantly greater pain relief over 48 hours when compared to an inactive oral capsule in phase II randomized, double-blind trials in patients undergoing abdominoplasty and bunionectomy [13, 14]. Interestingly, suzetrigine produced these results without producing opioid-related adverse effects such as drowsiness, constipation, respiratory depression, and overdose. Pharmacokinetic developments have examined suzetrigine tablet formulations, demonstrating that oral administration can be achieved in outpatient care settings [7].

Historical context of analgesic development: By binding to μ -opioid receptors in the central nervous system (CNS), opioids prevent pain signals. Despite its efficacy, this crucial mechanism has a variety of detrimental side effects that promote misuse, including euphoria, sedation, respiratory depression, and dependency [15]. NSAIDs reduce inflammation and prostaglandin synthesis by blocking cyclooxygenase (COX) enzymes. NSAIDs have the potential to cause gastrointestinal, renal, and cardiovascular toxicity, but they are safer in terms of addiction. Until the early 21st century, there was little clinical success with new targets such as transient receptor potential (TRP) channel inhibitors [16-18] and selective cannabinoid receptor modulators. Eventually, the focus of research shifted to gene-validated ion channels that are crucial for the transmission of pain, such as the voltage-gated sodium (NaV) channel subtypes expressed in nociceptors.

Nav1.8 sodium channels: Transmembrane proteins called voltage-gated sodium channels are essential for the start and spread of action potentials in excitable cells. The Nav1.8 subtype of the NaV family is primarily expressed in peripheral dorsal root ganglion (DRG) sensory neurons, which are the main afferent neurons that transmit nociceptive (pain) signals to the brain and spinal cord [19]. Nav1.8 has distinct biophysical characteristics. It sustains action potentials at lower temperatures and activates at greater depolarized potentials. This distinguishes it from other NaV subtypes involved in CNS or cardiac function. Nav1.8 was a desirable therapeutic target since it is primarily absent from the central nervous system. It has the ability to relieve pain without causing major adverse effects [20]. Suzetrigine - formerly known as VX-548 - was designed to exploit this target. Its high selectivity for Nav1.8 and unique interaction with the channel sets it apart from earlier, less specific sodium channel blockers [21].

Chemistry of suzetrigine: 4-[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-amido]pyridine-2-carboxamide is the drug's chemical name. Its molecular formula is C₂₁H₂₀F₅N₃O₄, and its molecular weight is 473.39 g/mol. Suzetrigine is essentially insoluble in water and is a white to off-white solid. Vertex Pharmaceuticals documented the drug's chemical production in a number of patents [22]. A different technique for making Suzetrigine was recently described as being environmentally friendly [23]. According to the patent, the method's benefits include fewer stages, a safer reaction, avoidance of the use and discharge of an ammonia methanol solution, and the potential racemization risk associated with preparing acid into acyl chloride.

Mechanism of action: The Nav1.8 sodium channel isoform, which is mostly expressed in peripheral nociceptors, is very selectively inhibited by suzetrigine through a new mechanism [19, 24]. In contrast to non-selective sodium channel blockers, suzetrigine selectively binds to the Nav1.8 sodium channel's voltage-sensing domain 2 (VSD2), maintaining the channel in its closed state via allosteric modulation. Several therapeutic benefits result from this special mechanism: Peripheral restriction: low CNS penetration, brain plasma ratio <0.1, prevents opioid-like central effects; Extraordinary selectivity: 31,000-fold higher affinity for Nav1.8 compared to other sodium channel subtypes (Nav1.1, Nav1.7, and Nav1.9); and Functional selectivity: Prevents pain transmission without totally blocking neurons [19, 25, 26]. Unprecedented insights into the structural pharmacology of Nav1.8 have also been revealed by recent structural investigations employing cryogenic electron microscopy (cryo-EM) and structure-based predictive modeling. However, the structure of Nav1.8 with VX-548 has not yet been established [27].

Clinical impact: When compared to a placebo, suzetrigine significantly reduced immediate pain after bunionectomy or abdominoplasty. Its effectiveness is similar to that of therapy with hydrocodone/acetaminophen (HB/APAP). The majority of adverse events (AEs) in phases II and III studies were categorized as mild to moderate in intensity, indicating that suzetrigine was generally well tolerated. It is noteworthy that three subjects had unrelated significant adverse events (SAEs) [13, 28]. Suzetrigine demonstrated good levels of patient satisfaction in individuals with a variety of surgical and non-surgical acute pain situations in the Phase III-Single-Arm: Mixed Acute Pain study. In particular, 83.2% of participants said they had a good, very good, or excellent experience [13]. All subgroups responded positively, with 82.0% of

surgical patients and 91.2% of non-surgical patients having good results. These outcomes demonstrate Suzetrigine's adaptability in a range of therapeutic contexts. Additionally, the majority of adverse events were categorized as mild to severe [14]. Randomized, double-blind, placebo- and active-controlled Phase III trials involving patients with acute postoperative pain, such as following abdominoplasty or bunionectomy, showed that suzetrigine was effective. When compared to a placebo, suzetrigine demonstrated statistically significant better pain relief in these trials. Although the drug's analgesic strength is typically described as modest in comparison to full-dose opioids, analgesic effects were comparable to established opioid combinations in certain measures [14, 29]. The Phase II-Lumbosacral Radiculopathy study assessed the impact of Suzetrigine on the treatment of persistent neuropathic pain [30]. At the 12-week evaluation, suzetrigine caused a mean decrease of 2.02 points on the numeric pain rating scale (NPRS) from baseline, whereas the placebo group had a decrease of 1.98 points. Suzetrigine was generally well tolerated, with AEs reported in 22.9% of patients taking suzetrigine compared to 32.4% in the placebo group, which is consistent with findings from other clinical studies. No SAEs were linked to the use of suzetrigine, and the majority of AEs were classified as mild or moderate.

Conclusion: The FDA's approval of suzetrigine, the first non-opioid analgesic class to be introduced in more than 20 years, is a significant development in pain management. Suzetrigine provides efficient relief from moderate to severe acute pain without the addiction and central nervous system risks associated with opioids by specifically targeting peripheral NaV1.8 sodium channels. Suzetrigine is an essential addition to the analgesic toolbox, despite ongoing difficulties such as a small analgesic effect size, a lack of long-term data, and financial concerns. Suzetrigine has the potential to revolutionize acute pain management and usher in a new era of non-opioid pain treatments as more research is conducted.

References

1. Mills SEE, Nicolson KP, Smith BH. Chronic pain: A review of its epidemiology and associated factors in population-based studies. *British Journal of Anesthesia*. 2019; 123(2): e273-e283. doi: 10.1016/j.bja.2019.03.023
2. Syed Nizamuddin SF. Xylazine-fentanyl crisis in North America: Epidemiology, clinical impact, and harm reduction. *Mediterranean Journal of Medicine and Medical Sciences*. 2025; 1(2): 32-36. doi: 10.5281/zenodo.17058720
3. Schafer-Kavvadias S. Improvement of opioid addiction medication through extended-release naltrexone: a comparative, experimental, and laboratory approach. *Mediterranean Journal of Pharmacy and Pharmaceutical Sciences*. 2023; 3(1): 3-5. doi: 10.5281/zenodo.7771314
4. Preuss CV, Kalava A, King KC. Prescription of controlled substances: Benefits and risks. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025; PMID: 30726003. Bookshelf ID: NBK537318.
5. Cunico D, Rossi A, Verdesca M, Principi N, Esposito S. Pain management in children admitted to the emergency room: A narrative review. *Pharmaceuticals*. 2023; 16(8): 1178. doi: 10.3390/ph16081178
6. Akter B, Aishee S, Hridoy A, Pulok MMH, Islam MA, Biswas A, et al. Structural tailoring of etoricoxib: A spectrochemical, medicinal and pharmacological study. *Chemical Physics Impact*. 2025; 10: 100830. doi: 10.1016/j.chphi.2025.100830
7. Shallof NM, Abduekarem AR. Suzetrigine mechanism, efficacy, and clinical implications: A narrative review. *Mediterranean Journal of Pharmacy and Pharmaceutical Sciences*. 2025; 5(4): 90-95. doi: 10.5281/zenodo.18008693
8. The U.S. Food and Drug Administration. FDA approves novel non-opioid treatment for moderate to severe acute pain. 2025; press announcement. For Immediate Release: January 30, 2025.
9. Mackieh R, Abou-Nader R, Wehbe R, Mattei C, Legros C, Fajloun Z, Sabatier JM. Voltage-gated sodium channels: A prominent target of marine toxins. *Marine Drugs*. 2021; 19(10): 562. doi: 10.3390/md19100562
10. Heinle JW, Dalessio S, Janicki P, Ouyang A, Vrana KE, et al. Insights into the voltage-gated sodium channel, NaV1.8, and its role in visceral pain perception. *Frontiers in Pharmacology*. 2024; 15: 1398409. doi: 10.3389/fphar.2024.1398409
11. Hameed S. Nav1.7 and Nav1.8: Role in the pathophysiology of pain. *Molecular Pain*. 2019; 15: 1744806919858801. doi: 10.1177/1744806919858801

12. Rai MA, Bhat R, Shabaraya. Knowledge, attitudes, and practice of pharmacists in opioid abuse prevention: A cross-sectional study in Mangalore, India. *Mediterranean Journal of Medical Research*. 2025; 2(2): 38-44. doi: 10.5281/zenodo.15455698
13. Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D, et al. VX21-548-101 and VX21-548-102 trial groups. Selective inhibition of NaV1.8 with VX-548 for acute pain. *The New England Journal of Medicine*. 2023; 389(5): 393-405. doi: 10.1056/NEJMoa2209870
14. McCoun J, Winkle P, Solanki D, Urban J, Bertoch T, Oswald J, et al. Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: A phase 3 single-arm study for surgical or non-surgical acute pain. *Journal of Pain Research*. 2025; 18: 1569-1576. doi: 10.2147/JPR.S509144
15. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse; Phillips JK, Ford MA, Bonnie RJ, editors. Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use. Washington (DC): National Academies Press (US); 2017; 2: Pain Management and the Intersection of Pain and Opioid Use Disorder: Bookshelf ID: NBK458655
16. Kaneko Y, Szallasi A. Transient receptor potential (TRP) channels: A clinical perspective. *British Journal of Pharmacology*. 2014; 171(10): 2474-507. doi: 10.1111/bph.12414
17. Schumacher MA. Transient receptor potential channels in pain and inflammation: Therapeutic opportunities. *Pain Practice*. 2010; 10(3): 185-200. doi: 10.1111/j.1533-2500.2010.00358.x
18. Hoque M. Mechanisms, clinical implications, and treatment strategies for autonomic health dysfunction in anxiety and depression. *Batna Journal of Medical Sciences*. 2025; 12(4): 28. doi: 10.48087/BJMSoa.2025.12428
19. Osteen JD, Immani S, Tapley TL, Indersmitten T, Hurst NW, Healey T, et al. Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain. *Pain Therapy*. 2025; 14(2): 655-674. doi: 10.1007/s40122-024-00697-0
20. Keam SJ. Suzetrigine: First approval. *Drugs*. 2025; 85(6): 845-851. doi: 10.1007/s40265-025-02178-w
21. Rajasingham R, Qi Y. Suzetrigine, a non-opioid small-molecule analgesic: Mechanism of action, clinical, and translational science. *Clinical and Translational Sciences*. 2025; 18(11): e70414. doi: 10.1111/cts.70414
22. Harrison C. Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels. WIPO (PCT), WO: WO2022256660A1. 8-12-2022.
23. Zhu F, Qin H. Shandong Fuchang Pharmaceutical Co., Ltd. Preparation method of suzetrigine. CN118772124A, 15-10-2024.
24. Osteen JD, Herzig V, Gilchrist J, Emrick JJ, Zhang C, Wang X, et al. Selective spider toxins reveal a role for the Nav1.1 channel in mechanical pain. *Nature*. 2016; 534(7608): 494-499. doi: 10.1038/nature17976
25. Kingwell K. NaV1.8 inhibitor poised to provide opioid-free pain relief. *Nature Reviews of Drug Discovery*. 2025; 24(1): 3-5. doi: 10.1038/d41573-024-00203-3
26. McCormack K, Santos S, Chapman ML, Krafte DS, Marron BE, West CW, et al. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. *Proceedings of the National Academy of Sciences USA*. 2013; 110(29): E2724-32. doi: 10.1073/pnas.1220844110
27. Wang H, Huang J, Zang J, Jin X, Yan N. Drug discovery targeting Nav1.8: Structural insights and therapeutic potential. *Current Opinion in Chemical Biology*. 2024; 83: 102538. doi: 10.1016/j.cbpa.2024.102538 Erratum in: *Current Opinion in Chemical Biology*. 2025; 84: 102546. doi: 10.1016/j.cbpa.2024.102546
28. ClinicalTrials.gov, Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in participants with painful Diabetic Peripheral Neuropathy (DPN), Clinical Trials. gov Identifier: NCT06696443.
29. Yale Medicine. CARRIE MACMILLAN February 21, 2025. https://www.yalemedicine.org/news/new-non-opioid-pain-pill?utm_source=chatgpt.com (Accessed 20 December 2025).
30. Vertex Pharmaceuticals [Internet], Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy (Vertex Pharmaceuticals, 2024).

Conflict of interest: The author declares the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethical issues: The author completely observed ethical issues, including plagiarism, informed consent, data fabrication or falsification, and double publication or submission.

Data availability statement: The raw data that support the findings of this article are available from the corresponding author upon reasonable request.

Author declarations: The authors confirms that they have followed all relevant ethical guidelines and obtained any necessary IRB and/or ethics committee approvals.

Generative AI disclosure: No generative AI was used in the preparation of this manuscript.